Pharma Pioneer

Antennova Concludes Initial Dosing in Phase I ATN-031 Trial

19 May 2024
2 min read

Antennova, a biopharmaceutical firm, has reached a significant milestone with the completion of the initial dosing group in a Phase I clinical trial for ATN-031, a pioneering anti-CD24 monoclonal antibody. The treatment is currently being tested in a multi-center, open-label study known as PERFORM, which is focused on patients with advanced solid tumors or B-cell non-Hodgkin's lymphoma (B-NHL). The trial is being led by The University of Texas MD Anderson Cancer Center and includes participation from four major U.S. cancer centers.

In the first cohort, five patients with late-stage cancer have been enrolled, and no dose-limiting toxicities have been observed. Notably, tumor reduction was detected in one patient who had undergone seven prior treatments. Jay Mei, M.D., Ph.D., the Founder and Chairman of Antennova, expressed gratitude for the participants and optimism for the early clinical indications observed in this challenging patient group.

ATN-031 is a novel humanized monoclonal antibody that targets CD24, a protein that cancer cells use to avoid detection and destruction by the immune system. Unlike CD47, another "don't eat me" signal, CD24 has a more limited presence in healthy tissues and is more prevalent in cancerous tissues. The antibody works by blocking the CD24-Siglec-10 interaction, which is a key mechanism of immune evasion in cancer cells. Early research has shown that ATN-031 can bind to CD24 with high specificity and trigger the phagocytosis of cancer cells by macrophages, while also promoting the production of pro-inflammatory cytokines.

Antennova, a subsidiary of Antengene, is dedicated to developing innovative therapies that target the tumor microenvironment to improve the efficacy of existing treatments and overcome resistance to checkpoint inhibitors. The company has four clinical-stage programs, including ATN-031, and has received Orphan Drug Designation from the FDA for two of its therapies.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

PHV Launches First Marburg Vaccine Clinical Trial
Pharma Pioneer
3 min read
PHV Launches First Marburg Vaccine Clinical Trial
19 May 2024
Public Health Vaccines has initiated a Phase 1 clinical trial for a novel vaccine candidate, PHV01, which targets the Marburg virus.
Read →
Theratechnologies Advances to Higher Dosage in Sudocetaxel Zendusortide Phase 1 Ovarian Cancer Trial
Pharma Pioneer
2 min read
Theratechnologies Advances to Higher Dosage in Sudocetaxel Zendusortide Phase 1 Ovarian Cancer Trial
19 May 2024
Theratechnologies Inc., has progressed to a higher dosage level in the third phase of its clinical trial for a drug called sudocetaxel zendusortide.
Read →
Promising Preliminary Results for BLB201 RSV Vaccine in Pediatric Clinical Trial
Pharma Pioneer
3 min read
Promising Preliminary Results for BLB201 RSV Vaccine in Pediatric Clinical Trial
19 May 2024
Blue Lake Biotechnology has released early findings from a Phase 1/2a clinical trial for BLB201.
Read →
Andelyn and Grace Science Collaborate on AAV Gene Therapy Manufacturing for NGLY1 Deficiency
Pharma Pioneer
3 min read
Andelyn and Grace Science Collaborate on AAV Gene Therapy Manufacturing for NGLY1 Deficiency
19 May 2024
Andelyn Biosciences has teamed up with Grace Science, LLC, to facilitate the technical transfer and production of GS-100, an AAV NGLY1 gene therapy for clinical trials.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.